{"id":"oseltamivir-oral","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"5","effect":"Abdominal pain"},{"rate":"2","effect":"Headache"},{"rate":"3","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1229","moleculeType":"Small molecule","molecularWeight":"312.41"},"_dailymed":{"setId":"11cf45d4-0e6c-4408-bbe6-5ed94468cf2e","title":"OSELTAMIVIR PHOSPHATE FOR ORAL SUSPENSION (OSELTAMIVIR PHOSPHATE) POWDER, FOR SUSPENSION [ORYZA PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir is a prodrug that is converted to its active form (oseltamivir carboxylate) in the body. The active metabolite inhibits influenza neuraminidase, an enzyme on the viral surface required for the virus to escape from infected host cells. By blocking neuraminidase, the drug prevents viral release and transmission to uninfected cells, thereby reducing the duration and severity of influenza infection.","oneSentence":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:46.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age"},{"name":"Prophylaxis of influenza A and B in patients ≥1 year of age"}]},"trialDetails":[{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT05648448","phase":"PHASE2","title":"A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2023-02-22","conditions":"Influenza, Influenza, Human","enrollment":3000},{"nctId":"NCT07357051","phase":"PHASE3","title":"Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","status":"RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-11-07","conditions":"Respiratory Viral Infection","enrollment":177},{"nctId":"NCT07229807","phase":"PHASE3","title":"Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-11-22","conditions":"Influenza a","enrollment":119},{"nctId":"NCT07095257","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza","status":"RECRUITING","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2025-10-13","conditions":"Respiratory Viral Infection","enrollment":168},{"nctId":"NCT06669351","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza","status":"TERMINATED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2024-10-31","conditions":"Respiratory Viral Infection","enrollment":98},{"nctId":"NCT07113392","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","startDate":"2025-08-01","conditions":"Influenza","enrollment":144},{"nctId":"NCT05818124","phase":"PHASE1","title":"Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-21","conditions":"Influenza Infection","enrollment":161},{"nctId":"NCT06774859","phase":"PHASE3","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2024-10-27","conditions":"Influenza","enrollment":100},{"nctId":"NCT02342249","phase":"PHASE2","title":"Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-11","conditions":"Influenza A","enrollment":292},{"nctId":"NCT06057103","phase":"PHASE1","title":"A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2023-08-28","conditions":"Drug Interaction","enrollment":18},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT03901001","phase":"PHASE3","title":"Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-08","conditions":"Influenza","enrollment":160},{"nctId":"NCT03900988","phase":"PHASE3","title":"Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-08","conditions":"Influenza","enrollment":160},{"nctId":"NCT05789342","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2023-02-15","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT04683406","phase":"PHASE3","title":"A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2020-12-28","conditions":"Influenza A","enrollment":750},{"nctId":"NCT04536415","phase":"PHASE4","title":"Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers","status":"COMPLETED","sponsor":"Austarpharma, LLC","startDate":"2020-08-25","conditions":"Bioequivalence","enrollment":96},{"nctId":"NCT04523090","phase":"PHASE2, PHASE3","title":"Catalysing the Containment of COVID-19","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2020-08-27","conditions":"COVID-19","enrollment":322},{"nctId":"NCT05378022","phase":"NA","title":"Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children","status":"COMPLETED","sponsor":"National Children's Hospital, Vietnam","startDate":"2020-12-21","conditions":"Acute Respiratory Tract Infections","enrollment":70},{"nctId":"NCT05297968","phase":"PHASE1","title":"Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-05-13","conditions":"Healthy Subjects","enrollment":72},{"nctId":"NCT04338698","phase":"PHASE3","title":"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","status":"COMPLETED","sponsor":"Shehnoor Azhar","startDate":"2020-04-22","conditions":"COVID 19","enrollment":550},{"nctId":"NCT05108051","phase":"PHASE1","title":"Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2020-11-19","conditions":"Drug-drug Interaction","enrollment":36},{"nctId":"NCT04303299","phase":"PHASE3","title":"Fight COVID-19 Trial","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-08-19","conditions":"SARS-COV-2 Infections, COVID-19","enrollment":320},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT02369159","phase":"PHASE3","title":"Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2015-03-11","conditions":"Influenza","enrollment":137},{"nctId":"NCT04684498","phase":"PHASE4","title":"Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2020-03-01","conditions":"ST Elevation Myocardial Infarction, STEMI","enrollment":382},{"nctId":"NCT02927431","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-01-19","conditions":"Virus Diseases","enrollment":10},{"nctId":"NCT03899571","phase":"NA","title":"Prophylactic Treatment With Oseltamivir","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2019-01-22","conditions":"Influenza, Human","enrollment":222},{"nctId":"NCT03520049","phase":"PHASE3","title":"Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2016-11","conditions":"Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT04361422","phase":"PHASE3","title":"Isotretinoin in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-12-01","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04297462","phase":"NA","title":"Different Regimens in Influenza Postexposure Chemoprophylaxis in Children","status":"UNKNOWN","sponsor":"Centre of Postgraduate Medical Education","startDate":"2016-11-17","conditions":"Influenza, Exposure, Prevention","enrollment":50},{"nctId":"NCT01965626","phase":"PHASE2","title":"A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP","status":"COMPLETED","sponsor":"Shandong University","startDate":"2016-02-01","conditions":"Thrombocytopenia","enrollment":96},{"nctId":"NCT03629184","phase":"PHASE3","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-20","conditions":"Influenza","enrollment":173},{"nctId":"NCT04323345","phase":"PHASE3","title":"Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2020-04-15","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT01850446","phase":"PHASE4","title":"Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2015-02-20","conditions":"Influenza","enrollment":184},{"nctId":"NCT02532283","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-12-11","conditions":"Influenza A Virus","enrollment":102},{"nctId":"NCT03903718","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2020-04-03","conditions":"Influenza","enrollment":""},{"nctId":"NCT02949011","phase":"PHASE3","title":"Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-01-11","conditions":"Influenza","enrollment":2184},{"nctId":"NCT02609399","phase":"PHASE4","title":"ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-11-01","conditions":"Influenza","enrollment":180},{"nctId":"NCT00844155","phase":"NA","title":"Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit","status":"WITHDRAWN","sponsor":"University of Manitoba","startDate":"2009-03","conditions":"Influenza A Virus Infection, Influenza B Virus Infection","enrollment":""},{"nctId":"NCT02469298","phase":"PHASE2","title":"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-01","conditions":"Virus Diseases","enrollment":45},{"nctId":"NCT03394209","phase":"PHASE2","title":"A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2018-02-06","conditions":"Influenza, Human, Critical Illness, Influenza","enrollment":34},{"nctId":"NCT02954354","phase":"PHASE3","title":"A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-12-08","conditions":"Influenza","enrollment":1436},{"nctId":"NCT03754686","phase":"PHASE4","title":"Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2019-02-10","conditions":"Influenza","enrollment":436},{"nctId":"NCT00803595","phase":"PHASE3","title":"A Multinational Phase III Study of CS-8958 (MARVEL)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-11","conditions":"Influenza, Human","enrollment":1002},{"nctId":"NCT02282384","phase":"PHASE4","title":"An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Pulmonary Disease, Influenza","enrollment":""},{"nctId":"NCT01715909","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-22","conditions":"Influenza","enrollment":20},{"nctId":"NCT01231620","phase":"PHASE3","title":"A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-15","conditions":"Influenza, Human","enrollment":626},{"nctId":"NCT03618407","phase":"","title":"Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2018-09-01","conditions":"Influenza Virus Infection","enrollment":120},{"nctId":"NCT00545532","phase":"PHASE3","title":"A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02-04","conditions":"Influenza, Human","enrollment":228},{"nctId":"NCT02293863","phase":"PHASE2","title":"A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-01-14","conditions":"Influenza","enrollment":168},{"nctId":"NCT02603952","phase":"PHASE1, PHASE2","title":"A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2015-12-07","conditions":"Influenza","enrollment":126},{"nctId":"NCT01610245","phase":"PHASE3","title":"Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2013-03","conditions":"Influenza","enrollment":1941},{"nctId":"NCT02561169","phase":"PHASE4","title":"A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza","status":"TERMINATED","sponsor":"McMaster University","startDate":"2015-12","conditions":"Influenza","enrollment":1},{"nctId":"NCT03023852","phase":"PHASE1","title":"A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2017-02-14","conditions":"Healthy","enrollment":45},{"nctId":"NCT00988325","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Influenza","enrollment":65},{"nctId":"NCT01980966","phase":"PHASE2","title":"A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-11-25","conditions":"Healthy Volunteer","enrollment":101},{"nctId":"NCT01179919","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects","status":"COMPLETED","sponsor":"Manjunath Prakash Pai","startDate":"2010-07","conditions":"Obesity","enrollment":21},{"nctId":"NCT02989012","phase":"PHASE2","title":"Phase IIaTrials of GanMaoKangNing Granules","status":"UNKNOWN","sponsor":"Dalian Zhen-Ao Bio-Tech Co., Ltd.","startDate":"","conditions":"Epidemic Influenza","enrollment":96},{"nctId":"NCT02780622","phase":"PHASE4","title":"A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Drug Therapy, Combination","enrollment":20},{"nctId":"NCT02941731","phase":"PHASE1","title":"Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-04","conditions":"Healthy","enrollment":32},{"nctId":"NCT01033734","phase":"PHASE1","title":"A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-12","conditions":"Influenza","enrollment":8},{"nctId":"NCT01172847","phase":"PHASE1","title":"A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT00949533","phase":"PHASE3","title":"A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Influenza","enrollment":37},{"nctId":"NCT01053663","phase":"PHASE1","title":"A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Influenza","enrollment":9},{"nctId":"NCT01556633","phase":"PHASE1","title":"A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-03","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT00412737","phase":"PHASE4","title":"A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Influenza","enrollment":477},{"nctId":"NCT02617784","phase":"PHASE1","title":"A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"End Stage Renal Disease","enrollment":24},{"nctId":"NCT02572583","phase":"PHASE1, PHASE2","title":"A Clinical Study of Treating Influenza With Liugan Shuangjie Heji","status":"UNKNOWN","sponsor":"Dongfang Hospital Beijing University of Chinese Medicine","startDate":"2014-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT00873886","phase":"PHASE1","title":"A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2009-04","conditions":"Pregnancy, Influenza","enrollment":""},{"nctId":"NCT00453999","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2007-07","conditions":"Influenza","enrollment":137},{"nctId":"NCT02262715","phase":"PHASE1","title":"A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-07","conditions":"Healthy","enrollment":38},{"nctId":"NCT01037634","phase":"PHASE2","title":"Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-03","conditions":"Influenza","enrollment":""},{"nctId":"NCT00298233","phase":"PHASE2","title":"High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"Influenza, Avian Influenza, Severe Influenza","enrollment":326},{"nctId":"NCT00979251","phase":"PHASE2","title":"Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2009-09","conditions":"Influenza","enrollment":2},{"nctId":"NCT01050257","phase":"PHASE3","title":"A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Influenza","enrollment":118},{"nctId":"NCT00391768","phase":"PHASE1, PHASE2","title":"Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Influenza","enrollment":87},{"nctId":"NCT01708369","phase":"PHASE1","title":"Alcohol Inhibits Drug Metabolism by Carboxylesterases","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2012-02","conditions":"Drug Interactions","enrollment":19},{"nctId":"NCT01032837","phase":"PHASE4","title":"A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Influenza","enrollment":102},{"nctId":"NCT01620307","phase":"PHASE2","title":"Rapamune Improves Outcomes of Severe H1N1 Pneumonia","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2009-06","conditions":"H1N1 Pneumonia, Hypoxemia","enrollment":38},{"nctId":"NCT00799760","phase":"PHASE3","title":"Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-12","conditions":"Gastric Influenza","enrollment":541},{"nctId":"NCT01388439","phase":"","title":"Pharmacokinetics of Oseltamivir in Newborns and Infants","status":"COMPLETED","sponsor":"St. Louis Children's Hospital","startDate":"2011-01","conditions":"Prematurity of Fetus","enrollment":19},{"nctId":"NCT01306773","phase":"NA","title":"Convalescent Plasma Treatment in Severe 2009 H1N1 Infection","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2009-12","conditions":"Influenza A","enrollment":80},{"nctId":"NCT01049763","phase":"PHASE1","title":"Open-Label Pharmacokinetic of Oseltamivir in Healthy Obese Thai Adult Subjects","status":"COMPLETED","sponsor":"South East Asia Infectious Disease Clinical Research Network","startDate":"2010-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00830323","phase":"PHASE2","title":"Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2009-01","conditions":"Influenza A Infection","enrollment":60},{"nctId":"NCT00980109","phase":"PHASE4","title":"Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-09","conditions":"Influenza","enrollment":390},{"nctId":"NCT00540501","phase":"PHASE1","title":"A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Healthy Subjects","enrollment":""},{"nctId":"NCT00921726","phase":"PHASE1","title":"Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-07","conditions":"Influenza, Virus Diseases","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oseltamivir(oral)","genericName":"Oseltamivir(oral)","companyName":"Guangdong Raynovent Biotech Co., Ltd","companyId":"guangdong-raynovent-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}